Key Points
- Extended Suspension: Dr Josevania Martins has received an extra six months’ suspension from the UK medical register after a review hearing.
- Original Verdict: The Hampstead-based doctor received a nine-month suspension in October 2025 by the Medical Practitioners Tribunal Service (MPTS).
- Misconduct Details: Dr Martins had been shown to be dishonest in prescribing weight loss drugs, namely Ozempic and Wegovy to her boyfriend, referred to as Mr B, from December 2023 to February 2024.
- Deception: While in a relationship with Mr B, Dr Martins kept him unaware of her professional nature by informing him that she got the prescription from a fellow physician.
- Falsifying Information: It was established by the tribunal that she mentioned a fictitious clinic name on the prescription as her clinical address, which she did citing her privacy issues.
- Breach of Law/Regulation/Ethics: The tribunal considered the act to be misleading and seriously dishonest on her part that made it impossible for her partner to give informed consent.
London (Extra London News) August 15, 2026 – A doctor practising in Camden has had her suspension from the medical register extended by six months following a review of her professional conduct. Dr Josevania Martins, who operates a private gynaecology and fertility clinic in Hampstead, was previously suspended for nine months in October 2025 after a tribunal found she had prescribed potent weight-loss injections to her then-boyfriend under deceptive circumstances.
Why was Dr Josevania Martins originally suspended?
As reported by Erin Dean of Doctors.net.uk, the Medical Practitioners Tribunal Service (MPTS) initially imposed a nine-month suspension after determining that Dr Martins acted with dishonesty while providing semaglutide—sold under the brand names Ozempic and Wegovy—to her partner, identified only as “Mr B”.
The tribunal heard that during their two-month relationship in late 2023 and early 2024, Dr Martins intentionally concealed her identity as a doctor from Mr B. When she provided the weight-loss medication, she informed him that the prescriptions had been facilitated by a medical colleague.
Clare Dyer, writing for The BMJ, noted that the tribunal evidence revealed Dr Martins used a fake clinic name on the prescription documents. Dr Martins, who qualified in Brazil in 1993 and has practised for over three decades, argued at the initial hearing that the use of a false clinic name was a “protective measure taken for her own privacy” and maintained that she was acting out of compassion during a perceived “medical emergency” when the patient’s own GP allegedly failed to intervene.
Explore more Camden News:
Camden Council Chalcots Estate Fire Safety Works London 2026
Tree Planting Via Social Value in Camden 2026
What were the findings of the Medical Practitioners Tribunal?
The tribunal, chaired by Louise Sweet, took a stern view of the deception. According to The BMJ, the chair stated that the consequence of Dr Martins’ actions was that the patient was deprived of the ability to give informed consent. Furthermore, the tribunal highlighted that by withholding her true identity, Dr Martins restricted Mr B’s ability to seek redress had any health complications arisen from the medication.
“It was ‘misleading and seriously dishonest’ to make up the name of a clinic and write it on a prescription,”
Ms Sweet added, as quoted by The BMJ. While the tribunal acknowledged that Dr Martins had not previously lapsed in her 31-year career and that Mr B reportedly did not regret the treatment, the seriousness of the dishonesty warranted significant disciplinary action.
What happened at the recent review hearing?
In a July 2026 review hearing, the MPTS determined that the original nine-month suspension was insufficient to fully address the concerns regarding her insight and remediation. Consequently, a further six-month suspension was imposed. The tribunal’s decision underscores the weight given to the ethical requirements surrounding professional boundaries, particularly when medical practitioners treat those with whom they share a close personal relationship.
What are the broader risks associated with Ozempic and Wegovy?
The case of Dr Martins has occurred against a backdrop of increasing regulatory scrutiny regarding the prescription and sale of weight-loss drugs. The Medicines and Healthcare products Regulatory Agency (MHRA) has issued multiple warnings regarding the distribution of potentially fake weight-loss pens in the UK.
In statements regarding the general safety of these medications, the MHRA has emphasised that such drugs must only be obtained via a legitimate, qualified prescriber. Dr Alison Cave, MHRA Chief Safety Officer, previously warned that procuring products such as Ozempic without a formal, valid prescription significantly increases the risk of receiving unlicensed or counterfeit goods, which do not meet safety and quality standards.
Professor Paul Gately, CEO of Obesity UK, also expressed concern over the criminal exploitation of patients seeking these treatments, reiterating the vital importance of ensuring that any pharmacological intervention is supervised by a registered medical professional. While medications like semaglutide are highly effective for managing diabetes and obesity, they remain prescription-only medicines for a reason, as they carry specific medical risks that require professional monitoring.
What is the current status of Dr Martins?
As of August 2026, the six-month extension maintains Dr Martins’ status as suspended from the UK medical register. Her case serves as a notable reminder of the General Medical Council’s (GMC) strict guidelines on doctor-patient relationships and the maintenance of transparency in medical practice. The tribunal’s insistence on a review to assess her “remediation and development of insight” indicates that the GMC continues to prioritise the integrity of the profession above the lengthy tenure of any individual practitioner.
The incident involving Mr B—who reportedly raised concerns with the GMC after the relationship ended, noting that Dr Martins had not even used her real name on dating applications—highlights the complexities and potential dangers when medical authority is leveraged outside of a formal, transparent clinical environment. As the medical community continues to navigate the high demand for new weight-loss therapies, regulators are signaling that they will continue to scrutinise any deviation from standard prescribing protocols, regardless of the practitioner’s prior professional standing.
Camden doctor suspension update
This video provides important context regarding the safety warnings and regulations surrounding the use of Ozempic and other GLP-1 weight loss medications in the current climate.
